Search

Displaying results 2631 - 2640 of 4345 in total
  1. Drug

    Darunavir

    go.drugbank.com/drugs/DB01264
    ApprovedInvestigational

    [A2278,A2281] It was initially approved by the FDA in 2006.

  2. Drug

    Ingenol mebutate

    go.drugbank.com/drugs/DB05013
    ApprovedWithdrawn

    Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.

  3. Drug

    Ribavirin

    go.drugbank.com/drugs/DB00811
    ApprovedInvestigational

    Ribavirin is added to decrease relapse rates by accelerating viral clearance early in the treatment course [A19645].

  4. Drug

    TAK-428

    go.drugbank.com/drugs/DB05499
    Experimental

    It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.

  5. Drug

    KDT-3594

    go.drugbank.com/drugs/DB17085
    Investigational

    KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.

  6. Drug

    MEM 1414

    go.drugbank.com/drugs/DB05888
    Experimental

    MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.

  7. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    Bendazac is an oxyacetic acid . Despite possessing anti-inflammatory, anti-necrotic, choleretic, and anti-lipidemic characteristics, most research has revolved around studying and demonstrating the agent's principal action in inhibiting ...

  8. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    [T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]

  9. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    It is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  10. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.